Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Siliq

- PMLiVE

Pfizer set to file Xeljanz for psoriasis

Set to add another indication after positive study results

- PMLiVE

Valeant offers $45.7bn for Botox firm Allergan

Trend for major pharma deals continues

Novartis building

Novartis pays $16bn for GSK’s oncology portfolio

Swiss company strikes series of deals, including one to step away from vaccines

- PMLiVE

Lilly’s stomach cancer drug cleared by FDA

Cyramza is tipped to reach blockbuster status depending on approvals

- PMLiVE

GSK gets OK in US for diabetes drug albiglutide

Once-weekly Tanzeum will compete against Victoza and Byetta after FDA approval

- PMLiVE

Changing the guard at Novartis’ Sandoz and Alcon units

Richard Francis joins from Biogen Idec and Kevin Buehler retires

- PMLiVE

Boehringer’s Pradaxa wins FDA backing for DVT

 Anticoagulant sees uses expanded in the US

- PMLiVE

FDA backs heroin overdose treatment

Evzio comes in auto injector to be used by family members or carers

Novartis building

Novartis replaces execs in Japan after investigation

Finds irregular practices in clinical trials programme

- PMLiVE

MannKind’s inhaled insulin backed for US approval

Afrezza finally on course for FDA approval in diabetes after two rejections

- PMLiVE

Doctors criticise FDA over Lemtrada rejection

Say Sanofi/Genzyme’s MS drug should have been approved

Novartis day

Novartis’ dual-action heart failure drug aces trial

Ends LCZ696 trial early on good results

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links